PDF(Pubmed)
Abstract：
UNASSIGNED: Advanced-stage hepatocellular carcinoma is a heterogeneous group with limited treatment options. TACE has been advocated recently by various study groups. The purpose of this study was to evaluate if TACE in combination with sorafenib, as well as TACE alone, was safe and efficacious in treating BCLC stage C HCC.
UNASSIGNED: A retrospective evaluation of the clinical data of 78 patients with BCLC stage C HCC who received either TACE-sorafenib (TS) combination therapy or TACE monotherapy as their first treatment was done. The two groups were compared in terms of radiological tumor response 1 month after the intervention. The two groups were also compared in terms of time to progression (TTP), overall survival (OS), and adverse events.
UNASSIGNED: The disease control rate (44.9% and 25.8%, respectively, P = 0.09) was higher in the TS combination group than in the TACE monotherapy group after 1 month of treatment. The TS combination group had significantly superior TTP and OS than the TACE group (TTP was 4.6 and 3.1 months, respectively, P = 0.001), and OS was 10.1 and 7.8 months, respectively, P < 0.001). The TACE-S group had a greater cumulative survival time at 6 months, 9 months, and 1 year than the TACE group (97.9%, 51.1%, 25.7% vs. 90.4%, 51.6%, and 0%, respectively).
UNASSIGNED: TS combination therapy in advanced-stage (BCLC-C) HCC significantly improved disease control rate, TTP, and OS compared with TACE alone, without any significant increase in adverse reactions.
UNASSIGNED: A retrospective evaluation of the clinical data of 78 patients with BCLC stage C HCC who received either TACE-sorafenib (TS) combination therapy or TACE monotherapy as their first treatment was done. The two groups were compared in terms of radiological tumor response 1 month after the intervention. The two groups were also compared in terms of time to progression (TTP), overall survival (OS), and adverse events.
UNASSIGNED: The disease control rate (44.9% and 25.8%, respectively, P = 0.09) was higher in the TS combination group than in the TACE monotherapy group after 1 month of treatment. The TS combination group had significantly superior TTP and OS than the TACE group (TTP was 4.6 and 3.1 months, respectively, P = 0.001), and OS was 10.1 and 7.8 months, respectively, P < 0.001). The TACE-S group had a greater cumulative survival time at 6 months, 9 months, and 1 year than the TACE group (97.9%, 51.1%, 25.7% vs. 90.4%, 51.6%, and 0%, respectively).
UNASSIGNED: TS combination therapy in advanced-stage (BCLC-C) HCC significantly improved disease control rate, TTP, and OS compared with TACE alone, without any significant increase in adverse reactions.
摘要：
■晚期肝细胞癌是一个异质性群体，治疗选择有限。TACE最近被各种研究小组提倡。这项研究的目的是评估TACE联合索拉非尼，以及单独的TACE，治疗BCLCC期HCC安全有效。
■对78例BCLCC期HCC患者的临床数据进行回顾性评估，这些患者接受TACE-索拉非尼（TS）联合治疗或TACE单药治疗作为其首次治疗。干预后1个月比较两组肿瘤的放射学反应。比较两组患者的进展时间(TTP),总生存期（OS），和不良事件。
■疾病控制率（44.9%和25.8%，分别,治疗1个月后，TS组合组的P=0.09）高于TACE单药治疗组。TS联合组TTP和OS明显优于TACE组(TTP分别为4.6和3.1个月,分别,P=0.001),OS分别为10.1和7.8个月，分别,P<0.001)。TACE-S组在6个月时的累积生存时间更长，9个月,和1年比TACE组(97.9%，51.1%,25.7%与90.4%,51.6%,0%,分别)。
■TS联合治疗晚期（BCLC-C）HCC可显着提高疾病控制率，TTP,和操作系统与单独的TACE相比，没有任何显著增加的不良反应。
■对78例BCLCC期HCC患者的临床数据进行回顾性评估，这些患者接受TACE-索拉非尼（TS）联合治疗或TACE单药治疗作为其首次治疗。干预后1个月比较两组肿瘤的放射学反应。比较两组患者的进展时间(TTP),总生存期（OS），和不良事件。
■疾病控制率（44.9%和25.8%，分别,治疗1个月后，TS组合组的P=0.09）高于TACE单药治疗组。TS联合组TTP和OS明显优于TACE组(TTP分别为4.6和3.1个月,分别,P=0.001),OS分别为10.1和7.8个月，分别,P<0.001)。TACE-S组在6个月时的累积生存时间更长，9个月,和1年比TACE组(97.9%，51.1%,25.7%与90.4%,51.6%,0%,分别)。
■TS联合治疗晚期（BCLC-C）HCC可显着提高疾病控制率，TTP,和操作系统与单独的TACE相比，没有任何显著增加的不良反应。
